117 related articles for article (PubMed ID: 35428585)
1. Axitinib Trough Concentration and its Influence on the Efficacy and Toxicity of Second-line Renal Cell Carcinoma Treatment.
Synowiec Z; Sobańska K; Synowiec T; Teżyk A; Tomczak P; Jabłecka A
Clin Genitourin Cancer; 2022 Aug; 20(4):390.e1-390.e8. PubMed ID: 35428585
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of Axitinib After Nivolumab Failure in Metastatic Renal Cell Carcinoma.
Ishihara H; Takagi T; Kondo T; Fukuda H; Tachibana H; Yoshida K; Iizuka J; Okumi M; Ishida H; Tanabe K
In Vivo; 2020; 34(3):1541-1546. PubMed ID: 32354960
[TBL] [Abstract][Full Text] [Related]
3. Pazopanib Exposure Relationship with Clinical Efficacy and Safety in the Adjuvant Treatment of Advanced Renal Cell Carcinoma.
Sternberg CN; Donskov F; Haas NB; Doehn C; Russo P; Elmeliegy M; Baneyx G; Banerjee H; Aimone P; Motzer RJ
Clin Cancer Res; 2018 Jul; 24(13):3005-3013. PubMed ID: 29330204
[No Abstract] [Full Text] [Related]
4. Axitinib versus sorafenib as second-line treatment for advanced renal cell carcinoma: overall survival analysis and updated results from a randomised phase 3 trial.
Motzer RJ; Escudier B; Tomczak P; Hutson TE; Michaelson MD; Negrier S; Oudard S; Gore ME; Tarazi J; Hariharan S; Chen C; Rosbrook B; Kim S; Rini BI
Lancet Oncol; 2013 May; 14(6):552-62. PubMed ID: 23598172
[TBL] [Abstract][Full Text] [Related]
5. Absorption of the orally active multikinase inhibitor axitinib as a therapeutic index to guide dose titration in metastatic renal cell carcinoma.
Fukudo M; Tamaki G; Azumi M; Kakizaki H; Matsumoto S; Tasaki Y
Invest New Drugs; 2021 Apr; 39(2):595-604. PubMed ID: 33098047
[TBL] [Abstract][Full Text] [Related]
6. Clinical outcomes of second-line treatment following prior targeted therapy in patients with metastatic renal cell carcinoma: a comparison of axitinib and nivolumab.
Suzuki K; Terakawa T; Furukawa J; Harada K; Hinata N; Nakano Y; Fujisawa M
Int J Clin Oncol; 2020 Sep; 25(9):1678-1686. PubMed ID: 32488547
[TBL] [Abstract][Full Text] [Related]
7. Phase 2 trial of neoadjuvant axitinib in patients with locally advanced nonmetastatic clear cell renal cell carcinoma.
Karam JA; Devine CE; Urbauer DL; Lozano M; Maity T; Ahrar K; Tamboli P; Tannir NM; Wood CG
Eur Urol; 2014 Nov; 66(5):874-80. PubMed ID: 24560330
[TBL] [Abstract][Full Text] [Related]
8. Clinical Factors Associated With Long-Term Benefit in Patients With Metastatic Renal Cell Carcinoma Treated With Axitinib: Real-World AXILONG Study.
Pinto Á; Reig O; Iglesias C; Gallardo E; García-Del Muro X; Alonso T; Anguera G; Suárez C; Muñoz-Langa J; Villalobos-León L; Rodríguez-Sánchez Á; Lainez N; Martínez-Ortega E; Campayo M; Velastegui A; Rodriguez-Vida A; Villa-Guzmán JC; Méndez-Vidal MJ; Rubio G; García I; Capdevila L; Lambea J; Vázquez S; Fernández O; Hernando-Polo S; Cerezo S; Santander C; García-Marrero R; Zambrana F; González-Del Alba A; Lazaro-Quintela M; Castellano D; Chirivella I; Anido U; Viana A; García A; Sotelo M; Arévalo MG; García-Donas J; Hernández C; Bolós MV; Llinares J; Climent MA
Clin Genitourin Cancer; 2022 Feb; 20(1):25-34. PubMed ID: 34789409
[TBL] [Abstract][Full Text] [Related]
9. Individualised axitinib regimen for patients with metastatic renal cell carcinoma after treatment with checkpoint inhibitors: a multicentre, single-arm, phase 2 study.
Ornstein MC; Pal SK; Wood LS; Tomer JM; Hobbs BP; Jia XS; Allman KD; Martin A; Olencki T; Davis NB; Gilligan TD; Mortazavi A; Rathmell WK; Garcia JA; Rini BI
Lancet Oncol; 2019 Oct; 20(10):1386-1394. PubMed ID: 31427205
[TBL] [Abstract][Full Text] [Related]
10. Axitinib versus sorafenib as first-line therapy in patients with metastatic renal-cell carcinoma: a randomised open-label phase 3 trial.
Hutson TE; Lesovoy V; Al-Shukri S; Stus VP; Lipatov ON; Bair AH; Rosbrook B; Chen C; Kim S; Vogelzang NJ
Lancet Oncol; 2013 Dec; 14(13):1287-94. PubMed ID: 24206640
[TBL] [Abstract][Full Text] [Related]
11. Axitinib with or without dose titration for first-line metastatic renal-cell carcinoma: a randomised double-blind phase 2 trial.
Rini BI; Melichar B; Ueda T; Grünwald V; Fishman MN; Arranz JA; Bair AH; Pithavala YK; Andrews GI; Pavlov D; Kim S; Jonasch E
Lancet Oncol; 2013 Nov; 14(12):1233-42. PubMed ID: 24140184
[TBL] [Abstract][Full Text] [Related]
12. Pembrolizumab plus axitinib versus sunitinib monotherapy as first-line treatment of advanced renal cell carcinoma (KEYNOTE-426): extended follow-up from a randomised, open-label, phase 3 trial.
Powles T; Plimack ER; Soulières D; Waddell T; Stus V; Gafanov R; Nosov D; Pouliot F; Melichar B; Vynnychenko I; Azevedo SJ; Borchiellini D; McDermott RS; Bedke J; Tamada S; Yin L; Chen M; Molife LR; Atkins MB; Rini BI
Lancet Oncol; 2020 Dec; 21(12):1563-1573. PubMed ID: 33284113
[TBL] [Abstract][Full Text] [Related]
13. Second line therapy with axitinib after only prior sunitinib in metastatic renal cell cancer: Italian multicenter real world SAX study final results.
Facchini G; Rossetti S; Berretta M; Cavaliere C; Scagliarini S; Vitale MG; Ciccarese C; Di Lorenzo G; Palesandro E; Conteduca V; Basso U; Naglieri E; Farnesi A; Aieta M; Borsellino N; La Torre L; Iovane G; Bonomi L; Gasparro D; Ricevuto E; De Tursi M; De Vivo R; Lo Re G; Grillone F; Marchetti P; De Vita F; Scavelli C; Sini C; Pisconti S; Crispo A; Gebbia V; Maestri A; Galli L; De Giorgi U; Iacovelli R; Buonerba C; Cartenì G; D'Aniello C
J Transl Med; 2019 Aug; 17(1):296. PubMed ID: 31464635
[TBL] [Abstract][Full Text] [Related]
14. Phase 2 Multicenter Single-Arm Study of Second-Line Axitinib in Favorable Risk Patients with Metastatic Renal Cell Carcinoma: FavorAx.
Tsimafeyeu I; Borisov P; Abdelgafur A; Leonenkov R; Novikova O; Guseva I; Demchenkova M; Mikhailova N; Semenov A; Yurmazov Z; Sivunova I; Ramazanova M; Gamayunov S; Kosov D; Bratslavsky G
Target Oncol; 2019 Feb; 14(1):33-38. PubMed ID: 30607698
[TBL] [Abstract][Full Text] [Related]
15. Second-line treatment with axitinib plus toripalimab in metastatic renal cell carcinoma: a retrospective multicenter study.
Huang J; Shi G; Wang Y; Wang P; Zhang J; Kong W; Huang Y; Wang S; Xue W
Future Oncol; 2022 Apr; 18(12):1461-1471. PubMed ID: 35103528
[TBL] [Abstract][Full Text] [Related]
16. Real-world dosing and drug costs with everolimus or axitinib as second targeted therapies for advanced renal cell carcinoma: a retrospective chart review in the US.
Pal SK; Jonasch E; Signorovitch JE; Reichmann WM; Li N; Liu Z; Perez JR; Vogelzang NJ
J Med Econ; 2016; 19(5):462-8. PubMed ID: 26652893
[TBL] [Abstract][Full Text] [Related]
17. Axitinib in first-line for patients with metastatic papillary renal cell carcinoma: Results of the multicentre, open-label, single-arm, phase II AXIPAP trial.
Negrier S; Rioux-Leclercq N; Ferlay C; Gross-Goupil M; Gravis G; Geoffrois L; Chevreau C; Boyle H; Rolland F; Blanc E; Ravaud A; Dermeche S; Flechon A; Albiges L; Pérol D; Escudier B;
Eur J Cancer; 2020 Apr; 129():107-116. PubMed ID: 32146304
[TBL] [Abstract][Full Text] [Related]
18. Overall survival and final efficacy and safety results from a Japanese phase II study of axitinib in cytokine-refractory metastatic renal cell carcinoma.
Eto M; Uemura H; Tomita Y; Kanayama H; Shinohara N; Kamei Y; Fujii Y; Umeyama Y; Ozono S; Naito S; Akaza H;
Cancer Sci; 2014 Dec; 105(12):1576-83. PubMed ID: 25283266
[TBL] [Abstract][Full Text] [Related]
19. Real world prospective experience of axitinib in metastatic renal cell carcinoma in a large comprehensive cancer centre.
Matias M; Le Teuff G; Albiges L; Guida A; Brard C; Bacciarelo G; Loriot Y; Massard C; Lassau N; Fizazi K; Escudier B
Eur J Cancer; 2017 Jul; 79():185-192. PubMed ID: 28511146
[TBL] [Abstract][Full Text] [Related]
20. Individualized Dosing of Axitinib Based on First-Dose Area Under the Concentration-Time Curve for Metastatic Renal-Cell Carcinoma.
Miura Y; Imamura CK; Uchino K; Kishida T; Matsubara N; Shinojima T; Kondo K; Hongo F; Yoshimura K; Tanigawara Y; Takano T
Clin Genitourin Cancer; 2019 Feb; 17(1):e1-e11. PubMed ID: 30529389
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
